Dr. R Garn Mabey—Past Clinical Trials

(Updated May 17,2012)

A Randomized Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Once Weekly XXXX and XXXX on Bone Mineral Density in Postmenopausal Women with Osteoporosis

An Open Label, Randomized Study of the Efficacy and Safety of an Intravaginal Right Delivering XXXX Compared to Commercially Available XXXX Oral Tablets in the Treatment of Bacterial Vaginosis

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Synthetic Conjugated Estrogens, XX 0.3 mg Tablets for the Treatment of Vulvovaginal Atrophy in Healthy Postmenopausal Women

A Multicenter, Randomized, Double Blind, Placebo-Controlled Study of Hormone XXXX and Hormone XXXX in a Conitinous Daily Regimen in Subjects with Premenstrual Dysphoric Disorder

A Multicenter, Double-Phase, Randomized, Double-Blind, Placebo Controlled (12-Week Double-Blind Followed by 12-Week Open-Label) Study Evaluating the Effect of XXER on Urgency Urinary Incontinence (UUI), Urgency, Frequency, Sexual Quality of Life and Sexual Function in Women with Overactive Bladder

A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effect of XXX90ug and XXXX 20 ug in a Continuous Daily Regimen on Cycle-Related Symptoms (CRS)

A Long-Term, Open-Label, Multicenter Study to Evaluate the Safety of a 1.3 g Oral Dose of a New Modified-Release XXX Formulation Administered Three Times Daily for up to 5 Days During the Menstrual Cycle in Women with Heavy Menstrual Bleeding Associated with Menorrhagia

Efficacy and Safety of XXX in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral XXX 30 mg and 60 mg Daily Doses with Placebo

Long-Term Safety of XXXX 60 mg Oral Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women without a Uterus: A 52-Week Open-Label Followup to Protocol XXXX

Long-Term Safety of 30 mg and 60 mg Oral Daily Doses of XXXX in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women with an Intact Uterus: A 40-Week Randomized, Double-Blind, Placebo-Controlled, Follow-Up to Protocol XXXX

A Double-Blind, Randomized, Placebo-and-Active Controlled Efficacy and Safety Study of XXX/Conjugated Estrogens Combinations for Prevention of Endometrial Hyperplasia and Prevention of Osteoporosis in Postmenopausal Women

A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study of the Selective Progesterone Receptor Modulator XXXX in Pre-Menopausal Women with Symptomatic Leiomyomata
A Randomized, Placebo-Controlled Phase II study of Multiple Dosing Regimens of Intravaginally Administered XXX Gel for the Treatment of Cervical High Risk HPV Infection

A Prospective, Multicenter, Double-Blinded, Randomized Study to Evaluate Bleeding Patterns in Women using One of Three Different Extended Cycle Oral Contraceptive Regimen XXX Compared to Seasonale Oral Contraceptive Regimen

A Multicenter, Open-Label, Dose Titration, Safety and Efficacy One Year Extension Study of the Selective Progesterone Receptor Modulator XXX in Pre-Menopausal Women with Symptomatic Leiomyomata who have previously completed study XXXX

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Trial of the Use of XXX Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix

The Effect of Dose Titration and Dose Tapering on the Tolerability of XXX in Women with Vasomotor Symptoms Associated with Menopause

A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study to Evaluate Efficacy and Safety of 0.65 g and 1.3 g Oral Doses of XX TID During Heavy Menstruation for the Treatment of Menorrhagia

Multicenter, Open-Label, Randomized Study to Assess the Safety and Contraceptive Efficacy of Two Doses (in Vitro 12 ug/24 h and 16 ug/24/h) of the Ultra Low Dose XXX Contraceptive Intrauterine Systems (LCS) for a maximum of 3 years in women 18 to 35 years of age

A Double-Blind, Randomized, Placebo-and Active Controlled Efficacy and Safety Study of XXX/Conjugated Estrogens Combinations for Prevention of Endometrial Hyperplasia and Prevention of Osteoporosis in Postmenopausal Women

A Multicenter, Open-Label Extension Study to Evaluate the Safety of a 1.3 g Oral Doses of XXX During Menstruation for the Treatment of Menorrhagia

A Multicenter, Randomized, Double-Blind Parallel Group Study to Evaluate the Efficacy and Safety of Two Doses of XXX Verses Placebo in Women with Overactive Bladder

A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, 2-arm Study to Show Superiority of the Oral Contraceptive XXX Over Ortho Tri-Cyclin Lo on Hormone Withdrawal-Associated Symptoms After 6 Cycles of Treatment

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of XXX for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Long-Term Safety and Efficacy of XXX for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
Efficacy and Safety of XXX in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated with Sexual Activity, Symptoms of Vulvar and Vaginal Atrophy (VVA), Associated with Menopause; A 12-Week Randomized Double-Blind, Placebo Controlled, Parallel-Group Study Comparing Oral Ospemifene 60 mg Daily Dose with Placebo in Postmenopausal Women

A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study of the Safety and Response Rate of 3 Subcutaneously Administered Doses of XXX in Patients with High Grade Cervical Intraepithelial Neoplasia Grade 2 or 3 Associated with High Risk HPV Infection

Multicenter, Open-Label, Uncontrolled Study to Investigate the Efficacy and Safety of the Transdermal Contraceptive Patch Containing XXX in a 21-Day Regimen for 13 Cycles in 1650 Healthy Female Subjects